drugset / Trial / NCT02874404
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase IIa trial studies the side effects and how well TGR-1202 and ibrutinib work in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement or does not respond to treatment. TGR-1202 and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2016-10-07
- Primary completion
- 2019-07-01
- Completion
- 2019-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |
| Subject | Umbralisib | Small molecule | — | Oral |